Aarti Drugs Future Growth
Future criteria checks 4/6
Aarti Drugs is forecast to grow earnings and revenue by 31.5% and 13.4% per annum respectively. EPS is expected to grow by 31.5% per annum. Return on equity is forecast to be 17.7% in 3 years.
Key information
31.5%
Earnings growth rate
31.5%
EPS growth rate
| Pharmaceuticals earnings growth | 18.3% |
| Revenue growth rate | 13.4% |
| Future return on equity | 17.7% |
| Analyst coverage | Low |
| Last updated | 25 Oct 2024 |
Recent future growth updates
Recent updates
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Sep 20
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet
Sep 05Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?
May 04Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models
Feb 01Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00
Jan 30Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think
May 17These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well
Nov 22We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet
Aug 28Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching
Aug 19Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value
May 17Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock
Apr 04Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?
Mar 17Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?
Feb 17Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio
Feb 04
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?
Jan 22Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth
Jan 07If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late
Dec 23Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly
Dec 08Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 23How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?
Nov 08Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)
Oct 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 32,612 | 3,107 | 1,443 | 2,943 | 1 |
| 3/31/2026 | 28,695 | 2,467 | 773 | 2,273 | 1 |
| 3/31/2025 | 24,560 | 1,561 | 1,315 | 3,315 | 1 |
| 9/30/2024 | 23,796 | 1,522 | 1,019 | 3,082 | N/A |
| 6/30/2024 | 24,228 | 1,568 | N/A | N/A | N/A |
| 3/31/2024 | 25,286 | 1,714 | 1,326 | 3,589 | N/A |
| 12/31/2023 | 26,510 | 1,802 | N/A | N/A | N/A |
| 9/30/2023 | 27,090 | 1,802 | 1,213 | 3,171 | N/A |
| 6/30/2023 | 27,552 | 1,794 | N/A | N/A | N/A |
| 3/31/2023 | 27,161 | 1,663 | -315 | 1,333 | N/A |
| 12/31/2022 | 26,679 | 1,656 | N/A | N/A | N/A |
| 9/30/2022 | 26,387 | 1,872 | -836 | 700 | N/A |
| 6/30/2022 | 25,306 | 1,910 | N/A | N/A | N/A |
| 3/31/2022 | 24,886 | 2,050 | -816 | 704 | N/A |
| 12/31/2021 | 22,961 | 2,014 | N/A | N/A | N/A |
| 9/30/2021 | 21,916 | 2,111 | 137 | 1,322 | N/A |
| 6/30/2021 | 21,901 | 2,438 | N/A | N/A | N/A |
| 3/31/2021 | 21,548 | 2,804 | 667 | 1,550 | N/A |
| 12/31/2020 | 21,027 | 2,876 | N/A | N/A | N/A |
| 9/30/2020 | 20,459 | 2,474 | 1,338 | 2,070 | N/A |
| 6/30/2020 | 19,453 | 2,044 | N/A | N/A | N/A |
| 3/31/2020 | 18,061 | 1,414 | 2,028 | 2,507 | N/A |
| 12/31/2019 | 18,156 | 1,100 | N/A | N/A | N/A |
| 9/30/2019 | 17,222 | 1,031 | N/A | N/A | N/A |
| 6/30/2019 | 15,921 | 888 | N/A | N/A | N/A |
| 3/31/2019 | 15,609 | 898 | 688 | 1,431 | N/A |
| 12/31/2018 | 14,136 | 863 | N/A | N/A | N/A |
| 9/30/2018 | 13,689 | 887 | N/A | N/A | N/A |
| 6/30/2018 | 13,407 | 943 | N/A | N/A | N/A |
| 3/31/2018 | 12,436 | 823 | N/A | 698 | N/A |
| 12/31/2017 | 11,592 | 790 | N/A | N/A | N/A |
| 9/30/2017 | 11,340 | 735 | N/A | N/A | N/A |
| 6/30/2017 | 11,569 | 721 | N/A | N/A | N/A |
| 3/31/2017 | 11,952 | 818 | N/A | 1,748 | N/A |
| 12/31/2016 | 12,102 | 785 | N/A | N/A | N/A |
| 9/30/2016 | 11,856 | 776 | N/A | N/A | N/A |
| 6/30/2016 | 11,431 | 713 | N/A | N/A | N/A |
| 3/31/2016 | 11,349 | 687 | N/A | 1,333 | N/A |
| 12/31/2015 | 11,101 | 686 | N/A | N/A | N/A |
| 9/30/2015 | 11,047 | 744 | N/A | N/A | N/A |
| 6/30/2015 | 11,180 | 774 | N/A | N/A | N/A |
| 3/31/2015 | 10,943 | 773 | N/A | 1,046 | N/A |
| 12/31/2014 | 10,868 | 807 | N/A | N/A | N/A |
| 9/30/2014 | 10,490 | 721 | N/A | N/A | N/A |
| 6/30/2014 | 10,109 | 662 | N/A | N/A | N/A |
| 3/31/2014 | 9,699 | 608 | N/A | 954 | N/A |
| 12/31/2013 | 9,083 | 526 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AARTIDRUGS's forecast earnings growth (31.5% per year) is above the savings rate (6.7%).
Earnings vs Market: AARTIDRUGS's earnings (31.5% per year) are forecast to grow faster than the Indian market (18.1% per year).
High Growth Earnings: AARTIDRUGS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AARTIDRUGS's revenue (13.4% per year) is forecast to grow faster than the Indian market (10.2% per year).
High Growth Revenue: AARTIDRUGS's revenue (13.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AARTIDRUGS's Return on Equity is forecast to be low in 3 years time (17.7%).